• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Public Health . Anti-nucleocapsid antibody levels reflect post-acute sequelae of COVID-19 symptom burden in children

tetano

Editor, Senior Moderator
J Infect Public Health


. 2025 Oct 24;19(1):103020.
doi: 10.1016/j.jiph.2025.103020. Online ahead of print. Anti-nucleocapsid antibody levels reflect post-acute sequelae of COVID-19 symptom burden in children

Pei-Chi Chen[SUP] 1 [/SUP], Yu-Lung Hsu[SUP] 2 [/SUP], Chih-Yu Lin[SUP] 3 [/SUP], Xiao-Ling Liu[SUP] 4 [/SUP], Miao-Hsi Hsieh[SUP] 4 [/SUP], Hui-Ju Tsai[SUP] 5 [/SUP], Wen-Shuo Kuo[SUP] 4 [/SUP], Hui-Fang Kao[SUP] 6 [/SUP], Shulhn-Der Wang[SUP] 7 [/SUP], Yu-Shan Ho[SUP] 4 [/SUP], Cheng-Ye Cai[SUP] 4 [/SUP], Lawrence Shih-Hsin Wu[SUP] 8 [/SUP], Jiu-Yao Wang[SUP] 9 [/SUP]



Affiliations
Abstract

Background: Post-acute sequelae of COVID-19 (PASC) presents significant challenges in pediatric care due to the lack of standardized diagnostic criteria. Understanding the lingering effects of the virus in pediatric patients is paramount. This study aims to explore the clinical and immunological dimensions of pediatric PASC, with a focus on anti-nucleocapsid (anti-N) IgG.
Methods: The Diagnosis and Support for COVID-19 Children to Enhance Recovery (DISCOVER) cohort, initiated in July 2022, enrolled 92 children in central Taiwan. A specialized PASC condition scale was developed to assess multisystem symptoms. Blood biomarkers, immune cytokine and immune checkpoint protein levels, IgG against SARS-CoV-2 antigens, and virus nucleocapsid gene were measured.
Results: Higher PASC scores correlated positively with monocytes (R² = 0.284) and neutrophils (R² = 0.207), and negatively with eosinophils (R² = -0.275). Virus persistence was minimal within this study cohort. Although anti-N IgG, macrophage inflammatory protein-1 alpha (MIP-1α), interleukin (IL)-2, and IL-21 were significantly elevated in children with PASC, levels of these immune cytokines did not correlate with the PASC severity. Only anti-N IgG levels positively correlated with monocyte counts (R² = 0.230). ROC analysis further identified anti-N IgG as a predictor for PASC severity, with an optimal cutoff value of 11. Unsupervised clustering revealed that patients with higher anti-N IgG exhibited greater symptom severity.
Conclusions: These findings suggest that elevated anti-N IgG may serve as a potential biomarker for stratifying disease severity in pediatric PASC.

Keywords: SARS-CoV-2 infection; anti-nucleocapsid antibody; biomarker; coronavirus disease; pediatric; post-acute sequelae of COVID-19 (PASC).

 
Back
Top